US Drug Recall Register

FDA Drug Recalls

14,801 recalls, newest first

Class II · Moderate risk Terminated

Maxim Instant Foam Hand Sanitizer

Reason CGMP Deviations: Product manufactured using expired active ingredient, Benzalkonium chloride.

Midlab Incorporated D-1463-2022
Class III · Low risk Terminated

Nighttime Sleep-Aid

Reason Labeling: Not Elsewhere Classified: Carton incorrectly identifies product as doxylamine succinate HCl, however the product is doxylamine succinate.

LNK International, Inc. D-1472-2022
Class III · Low risk Terminated

Acetaminophen 500 mg tablet

Reason Failed Tablet/Capsule Specifications: Imprint "AP 325" is missing from the tablet.

Akron Pharma, Inc. NDC 71399-8022-01 D-1353-2022
Class III · Low risk Terminated

Acetaminophen 325 mg tablets

Reason Failed Tablet/Capsule Specifications: Imprint "AP 325" is missing from the tablet.

Akron Pharma, Inc. NDC 71399-8024-01 D-1352-2022
Class II · Moderate risk Terminated

Acetaminophen Injection

Reason Temperature Abuse: Product distributed in refrigerated trucks with labels attached to pallets indicating "Refrigerate Upon Arrival", however product is labeled to be stored in a controlled room temperature environment.

Baxter Healthcare Corporation NDC 36000-306-60 D-1348-2022
Class III · Low risk Terminated

Zynrelef

Reason Defective Delivery System: An incorrect 10 mL (12 mL) Luer (slip) syringe packaged in one lot of Zynrelef 400 mg/12 mg kit

Heron Therapeutics, INC. NDC 47426-301-02 D-1335-2022
Class II · Moderate risk Terminated

Difluprednate Ophthalmic Emulsion 0.05%

Reason Lack of Assurance of Sterility: Complaints received of defective container closure.

Cipla NDC 69097-341-35 D-1328-2022
Class I · High risk Terminated

Banana Boat hair & scalp defense

Reason Chemical contamination: presence of benzene

Edgewell Personal Care Brands, LLC D-0212-2024
Class II · Moderate risk Terminated

Rifampin Capsules

Reason CGMP Deviations:OOS result was observed in 1-Methyl-4-Nitroso Piperazine (MNP) impurity.

Lupin Pharmaceuticals Inc. D-1343-2022
Class III · Low risk Terminated

Azacitidine for Injection

Reason Subpotent Drug

Amerisource Health Services LLC NDC 68001-0313-56 D-1349-2022
Class III · Low risk Terminated

Azacitidine for Injection 100mg/vial Lyophilized Powder

Reason Subpotent Drug - Out of specification (OOS) result obtained during monitoring stability study for Assay. Results below specification.

Teva Pharmaceuticals USA Inc NDC 68001-313-56 D-1334-2022
Class I · High risk Terminated

SANGTER Energy Supplement Capsules

Reason Marketed Without An Approved NDA/ANDA: FDA analysis found the product to be tainted with sildenafil.

Distributor RFR, LLC. D-1333-2022
Class I · High risk Terminated

Sustango

Reason Marketed Without an Approved NDA/ANDA: Analytical testing showed the presence of tadalafil.

Ultra Supplement LLC D-1350-2022
Class II · Moderate risk Terminated

Matzim LA

Reason Failed Dissolution Specifications: below specification limits for dissolution.

Teva Pharmaceuticals USA Inc NDC 58544-692-30 D-1303-2022
Class II · Moderate risk Terminated

Matzim LA

Reason Failed Dissolution Specifications: below specification limits for dissolution.

Teva Pharmaceuticals USA Inc NDC 52544-691-30 D-1302-2022
Class III · Low risk Terminated

Lamotrigine Tablets

Reason Labeling: Label Error on Declared Strength

AVKARE Inc. NDC 42291-367-10 D-1329-2022
Class II · Moderate risk Terminated

Prednisone Tablets USP

Reason Presence of foreign tablet: 2.5 mg tablet in a 20 mg bottle of Prednisone Tablets

Strides Pharma Inc. NDC 64380-785-06 D-1330-2022
Class II · Moderate risk Terminated

Irbesartan Tablets

Reason Failed Dissolution Specifications

Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-447-90 D-1294-2022
Class II · Moderate risk Terminated

Irbesartan Tablets

Reason Failed dissolution specifications.

Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-448-90 D-1293-2022